229 related articles for article (PubMed ID: 21163759)
1. [Incidence, risk factors and prevention of cisplatin-induced nephrotoxicity in patients with lung cancer].
Losonczy G; Máthé C; Müller V; Szondy K; Moldvay J
Magy Onkol; 2010 Dec; 54(4):289-96. PubMed ID: 21163759
[TBL] [Abstract][Full Text] [Related]
2. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin nephrotoxicity aggravated by cardiovascular disease and diabetes in lung cancer patients.
Máthé C; Bohács A; Duffek L; Lukácsovits J; Komlosi ZI; Szondy K; Horváth I; Müller V; Losonczy G
Eur Respir J; 2011 Apr; 37(4):888-94. PubMed ID: 20650984
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the renal function using cystatin C level in the patients receiving cisplatin-based chemotherapy.
Kos FT; Sendur MA; Aksoy S; Sezer S; Civelek B; Yazici O; Yaman S; Eren T; Zengin N
Ren Fail; 2013; 35(5):705-10. PubMed ID: 23530579
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study.
Launay-Vacher V; Oudard S; Janus N; Gligorov J; Pourrat X; Rixe O; Morere JF; Beuzeboc P; Deray G;
Cancer; 2007 Sep; 110(6):1376-84. PubMed ID: 17634949
[TBL] [Abstract][Full Text] [Related]
6. Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors.
Skinner R; Parry A; Price L; Cole M; Craft AW; Pearson AD
Eur J Cancer; 2009 Dec; 45(18):3213-9. PubMed ID: 19850470
[TBL] [Abstract][Full Text] [Related]
7. Occult renal impairment is common in patients with peripheral vascular disease and normal serum creatinine.
Rashid ST; Salman M; Agarwal S; Hamilton G
Eur J Vasc Endovasc Surg; 2006 Sep; 32(3):294-9. PubMed ID: 16716614
[TBL] [Abstract][Full Text] [Related]
8. [Assessment of kidney function before cisplatin administration: the need for 24-hour urine collection].
Ptok M; Ptok A; Schwab M
HNO; 1989 Feb; 37(2):67-70. PubMed ID: 2703375
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin nephrotoxicity: experimental and clinical studies.
Daugaard G
Dan Med Bull; 1990 Feb; 37(1):1-12. PubMed ID: 2178884
[TBL] [Abstract][Full Text] [Related]
10. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods.
Stewart DJ; Dulberg CS; Mikhael NZ; Redmond MD; Montpetit VA; Goel R
Cancer Chemother Pharmacol; 1997; 40(4):293-308. PubMed ID: 9225947
[TBL] [Abstract][Full Text] [Related]
11. Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity.
Campbell AB; Kalman SM; Jacobs C
Cancer Treat Rep; 1983 Feb; 67(2):169-72. PubMed ID: 6681731
[TBL] [Abstract][Full Text] [Related]
12. [Change of creatinine clearance rate in accordance with aging in Japanese patients with head and neck cancer].
Nishimura G; Horiuchi C; Yoshida T; Kawakami M; Yabuki K; Taguchi T; Nagao J; Kondo N; Masuda Y; Matsuda H; Mikami Y; Tsukuda M
Gan To Kagaku Ryoho; 2006 Apr; 33(4):463-6. PubMed ID: 16612154
[TBL] [Abstract][Full Text] [Related]
13. Importance of monitoring renal function in patients with cancer.
Aapro M; Launay-Vacher V
Cancer Treat Rev; 2012 May; 38(3):235-40. PubMed ID: 21605937
[TBL] [Abstract][Full Text] [Related]
14. A comparison of the rates of cisplatin (cDDP)--induced nephrotoxicity associated with sodium loading or sodium loading with forced diuresis as a preventative measure.
Leu L; Baribeault D
J Oncol Pharm Pract; 2010 Sep; 16(3):167-71. PubMed ID: 19759050
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin nephrotoxicity in a patient with a single kidney.
Udeani GO; Singh K; Mullane MR; Lad TE
Ann Pharmacother; 1996; 30(7-8):782-6. PubMed ID: 8826561
[TBL] [Abstract][Full Text] [Related]
16. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
17. Maitake beta-glucan enhances therapeutic effect and reduces myelosupression and nephrotoxicity of cisplatin in mice.
Masuda Y; Inoue M; Miyata A; Mizuno S; Nanba H
Int Immunopharmacol; 2009 May; 9(5):620-6. PubMed ID: 19249389
[TBL] [Abstract][Full Text] [Related]
18. Amelioration of cisplatin-induced nephrotoxicity by extracts of Hemidesmus indicus and Acorus calamus.
Sandeep D; Krishnan Nair CK
Pharm Biol; 2010 Mar; 48(3):290-5. PubMed ID: 20645815
[TBL] [Abstract][Full Text] [Related]
19. [Preventive effect of prostaglandin E1 on cisplatin-induced nephrotoxicity].
Takayama K; Nakanishi Y; Takano K; Harada T; Inoue K; Osaki S; Minami T; Hara N
Gan To Kagaku Ryoho; 1999 Mar; 26(4):503-8. PubMed ID: 10097747
[TBL] [Abstract][Full Text] [Related]
20. Baseline renal function screening.
Lameire N; Adam A; Becker CR; Davidson C; McCullough PA; Stacul F; Tumlin J;
Am J Cardiol; 2006 Sep; 98(6A):21K-26K. PubMed ID: 16949377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
